All individual numbers are from the SEC provided Financial Statement and Notes Data Sets. No guarantee is made for their accuracy. This report only shows the values that are common to a significant number of companies.
ABCELLERA BIOLOGICS INC. Last Reported: 6/30/2021 Stock Symbol: ABCL

Business Address

2215 YUKON STREET

VANCOUVER, BC CA V5Y 0A1

Mailing Address

2215 YUKON STREET

VANCOUVER, BC CA V5Y 0A1
Phone Number: (604) 559-9005 / State Incorporated: BC / Fiscal Year End 12/31

Balance Sheet

Date 6/30/2021 3/31/2021 12/31/2020 6/30/2020 3/31/2020 12/31/2019
Cash and Cash Equivalents $792,571,000.00 $685,795,000.00 $594,116,000.00 -- -- --
Accounts Receivable Net Current $2,799,000.00 $23,371,000.00 $903,000.00 -- -- --
Inventory -- -- -- -- -- --
Prepaid Expenses and Other Current Assets -- -- -- -- -- --
Total Current Assets $864,002,000.00 $907,982,000.00 $813,325,000.00 -- -- --
Property Plant and Equipement $87,479,000.00 $34,618,000.00 $17,923,000.00 -- -- --
Intangible Assets Net $110,223,000.00 $112,688,000.00 $115,153,000.00 -- -- --
Goodwill $31,500,000.00 $31,500,000.00 $31,500,000.00 -- -- --
Other Assets $15,947,000.00 $9,548,000.00 $8,388,000.00 -- -- --
Total Assets $1,151,856,000.00 $1,128,523,000.00 $1,005,536,000.00 -- -- --
Accounts Payable -- -- -- -- -- --
Accrued Liabilities -- -- -- -- -- --
Total Current Liabilities $184,177,000.00 $171,399,000.00 $175,028,000.00 -- -- --
Long Term Debt -- -- -- -- -- --
Additional Paid-in Capital $21,669,000.00 $14,562,000.00 $5,919,000.00 -- -- --
Accumulated Other Comprehensive Loss $2,152,000.00 -- -- -- -- --
Accumulated Deficit $229,100,000.00 $231,423,000.00 $114,202,000.00 -- -- --
Total Stockholders' Equity $967,679,000.00 $957,124,000.00 $830,508,000.00 $90,892,000.00 $83,689,000.00 $10,252,000.00
Controlling Interest in Subsidiaries -- -- -- -- -- --
Total Liabilities and Equity $1,151,856,000.00 $1,128,523,000.00 $1,005,536,000.00 -- -- --

Statement of Operations

Date 6/30/2021 3/31/2021 12/31/2020 6/30/2020 3/31/2020 12/31/2019
Total Revenues -- -- -- -- -- --
Cost of Revenues -- -- -- -- -- --
Gross Profit -- -- -- -- -- --
Research and Development $27,403,000.00 $12,352,000.00 -- $9,144,000.00 $4,118,000.00 --
Selling, General, and Administrative -- -- -- -- -- --
Total Operating Expenses $79,409,000.00 $44,667,000.00 -- $18,861,000.00 $6,779,000.00 --
Loss from Operations $150,975,000.00 $158,074,000.00 -- $-2,976,000.00 $-2,122,000.00 --
Loss Before Income Taxes $159,414,000.00 $161,487,000.00 -- $4,610,000.00 $-2,093,000.00 --
Earnings Per Share Basic $0.42 $0.43 -- $0.02 $-0.01 --
Weighted Average Shares Basic 270,953,541 269,697,212 -- 152,326,424 151,859,924 --
Earnings Per Share Diluted $0.36 $0.37 -- $0.03 $-0.01 --
Weighted Average Shares Diluted 321,555,443 320,282,747 -- 226,039,616 151,859,924 --
Common Stock Shares Authorized -- -- -- -- -- --
Common Stock Shares Outstanding 276,982,678 270,925,930 269,497,768 -- -- --
Common Stock Value $714,758,000.00 $711,139,000.00 $710,387,000.00 -- -- --
Common Stock Par Or Stated Value Per Share -- -- -- -- -- --
Payments Of Dividends Common Stock -- -- -- -- -- --
Preferred Stock Shares Authorized -- -- -- -- -- --
Preferred Stock Shares Outstanding -- -- -- -- -- --
Preferred Stock Value -- -- -- -- -- --
Preferred Stock Par Or Stated Value Per Share -- -- -- -- -- --
Share Price -- -- -- -- -- --
Copyright 2021 PursePoor.com